Additional file 3 of Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy

Additional file 3: Table 2. Disease status and treatment outcomes at CART2.-: no follow-up. *, MRD-negative CR was obtained after chemotherapy. CART2 was performed to prevent a recurrence. #, Pt01 relapsed after CART2 and received a third CAR-T salvage therapy. + : On the fourth day after CART2 reinfusion, pt04 began to develop testicular edema, along with redness and pain. After a week, the mass gradually shrank, and the tissue returned to normal size.

附加文件3：表2。CART2治疗时的疾病状态与治疗结局。
-：无随访数据。
*：化疗后获得微小残留病（Minimal Residual Disease, MRD）阴性的完全缓解（Complete Remission, CR），遂行CART2治疗以预防肿瘤复发。
#：患者Pt01于CART2治疗后复发，接受了第三次嵌合抗原受体T细胞（Chimeric Antigen Receptor T-Cell, CAR-T）挽救治疗。
+：CART2回输后第4天，患者pt04出现睾丸水肿，伴发红与疼痛。1周后肿物逐渐缩小，受累组织恢复正常大小。